- Home
- ARR vs IOVA Comparison
ARR vs IOVA Comparison
Compare ARR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | IOVA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | ARR | IOVA |
|---|---|---|
| Price | $17.78 | $4.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $18.00 | $9.11 |
| AVG Volume (30 Days) | 3.1M | ★ 15.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 16.18% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $49.14 |
| Revenue Next Year | $8.84 | $51.69 |
| P/E Ratio | $27.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.18 | $1.64 |
| 52 Week High | $19.31 | $5.63 |
Technical Indicators
Market Signals| Indicator | ARR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 71.61 |
| Support Level | $17.38 | $1.99 |
| Resistance Level | $18.54 | N/A |
| Average True Range (ATR) | 0.38 | 0.44 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 67.63 | 71.70 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.